echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > TAVO in combination with OPDIVO as a new complementary therapy for melanoma: the first time a patient has been given a drug in a Phase II trial

    TAVO in combination with OPDIVO as a new complementary therapy for melanoma: the first time a patient has been given a drug in a Phase II trial

    • Last Update: 2021-01-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Melanoma is a cancer developed from melanin cells and is a rare form of skin cancer.
    good for the skin but may also appear in the mouth, intestines or eyes.
    most commonly in the legs in female patients, while male patients are most commonly found in the back.
    pharmaceutical company OncoSec announced today that the first patient has been treated with the in-tumor DNA plasmid TAVO (tavokinogene telseplasmid) anti-PD-1 checkpoint inhibitor OPDIVO (nivolumab).
    phase II trial was designed to assess the effectiveness of TAVO combined OPDIVO as a new complementary therapy for patients with advanced melanoma.
    clinical results have been shown when opdivo (nivolumab), an anti-PD1 checkpoint inhibitor, is used as a new complementary therapy, rapid recurrence remains a problem for many patients.
    TAVO combined OPDIVO may promote a deep anti-tumor response and completely eliminate tumors before surgery, resulting in long-term clinical improvements for a significant proportion of patients treated.
    combination of TAVO with another anti-PD-1 checkpoint inhibitor, KEYTRUDA (pembrolizumab), has been shown to improve the overall remission rate in patients with the checkpoint inhibitor refrectable metastasis melanoma.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.